Novartis购买凯特治疗药物,价值高达1.1B美元,用于促进神经肌肉疾病的基因治疗。 Novartis buys Kate Therapeutics for up to $1.1B to boost gene therapy for neuromuscular diseases.

Novartis已经获得凯特治疗 高达11亿美元 以扩大其基因治疗 治疗神经肌肉疾病。 Novartis has acquired Kate Therapeutics for up to $1.1 billion to expand its gene therapy offerings for neuromuscular diseases. Kate 治疗学专门研究基因疗法,针对像Duchenne肌肉萎缩症这样的病症。 Kate Therapeutics specializes in gene therapies targeting conditions like Duchenne muscular dystrophy. 这笔交易包括先期付款和潜在的未来里程碑,目的是提高诺华公司治疗复杂的神经肌肉疾病的能力。 The deal includes upfront payments and potential future milestones, aiming to enhance Novartis' capabilities in treating complex neuromuscular diseases.